MARKET

FDMT

FDMT

4D Molecular Therapeutics Inc.
NASDAQ
3.750
-0.040
-1.06%
Closed 16:10 03/20 EDT
OPEN
3.740
PREV CLOSE
3.790
HIGH
3.845
LOW
3.670
VOLUME
645.94K
TURNOVER
0
52 WEEK HIGH
36.25
52 WEEK LOW
3.660
MARKET CAP
173.63M
P/E (TTM)
-1.2575
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FDMT last week (0310-0314)?
Weekly Report · 4d ago
4D Molecular Therapeutics Is Maintained at Buy by B of A Securities
Dow Jones · 03/10 17:03
4D Molecular Therapeutics Price Target Cut to $40.00/Share From $42.00 by B of A Securities
Dow Jones · 03/10 17:03
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $40
Benzinga · 03/10 16:53
4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial
TipRanks · 03/10 12:10
4DMT ANNOUNCES FIRST PATIENTS ENROLLED IN 4FRONT-1 PHASE 3 CLINICAL TRIAL EVALUATING 4D-150 IN WET AMD
Reuters · 03/10 12:00
4D MOLECULAR THERAPEUTICS INC - 4FRONT-2 TRIAL EXPECTED TO INITIATE IN Q3 2025
Reuters · 03/10 12:00
Weekly Report: what happened at FDMT last week (0303-0307)?
Weekly Report · 03/10 09:27
More
About FDMT
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.